BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Akorn, Inc. (NASDAQ: AKRX) today announced that it has signed an exclusive licensing, development and supply agreement with Sofgen Pharmaceuticals, a privately-held company located in Sunrise, Florida. The agreement is intended to develop an ANDA oral drug product for women’s healthcare. The current market size is approximately $115 million, according to recent IMS sales data. Financial terms of the agreement were not disclosed.
